Visfatin Amplifies Cardiac Inflammation and Aggravates Cardiac Injury via the NF- κ B p65 Signaling Pathway in LPS-Treated Mice.

This study showed that visfatin amplifies the cardiac inflammatory response and aggravates cardiac injury through the p65 signaling pathway. Visfatin may be a clinical target for preventing cardiac injury in sepsis.